vs
AtriCure, Inc.（ATRC）与RE/MAX Holdings, Inc.（RMAX）财务数据对比。点击上方公司名可切换其他公司
AtriCure, Inc.的季度营收约是RE/MAX Holdings, Inc.的2.0倍（$140.5M vs $71.1M），AtriCure, Inc.同比增速更快（13.1% vs -1.8%），RE/MAX Holdings, Inc.自由现金流更多（$33.5M vs $18.4M），过去两年AtriCure, Inc.的营收复合增速更高（13.6% vs -4.7%）
AtriCure是一家专注于心房颤动及相关心脏病症治疗的医疗设备企业，研发并生产创新外科手术工具与疗法，主要服务北美、欧洲、亚太地区的医院、心脏外科中心及医疗机构，为微创心脏手术提供高效可靠的适配解决方案。
RE/MAX是全球知名的房地产特许经营机构，业务遍布全球一百多个国家和地区，旗下拥有数千家门店，总计超过十万名房产经纪人，在国际房产中介领域拥有极高的品牌知名度与市场影响力。
ATRC vs RMAX — 直观对比
营收规模更大
ATRC
是对方的2.0倍
$71.1M
营收增速更快
ATRC
高出14.9%
-1.8%
自由现金流更多
RMAX
多$15.1M
$18.4M
两年增速更快
ATRC
近两年复合增速
-4.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $140.5M | $71.1M |
| 净利润 | — | $1.4M |
| 毛利率 | 75.0% | — |
| 营业利润率 | 1.8% | 13.1% |
| 净利率 | — | 2.0% |
| 营收同比 | 13.1% | -1.8% |
| 净利润同比 | — | -75.2% |
| 每股收益（稀释后） | $0.04 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATRCRMAX
| Q4 25 | $140.5M | $71.1M | ||
| Q3 25 | $134.3M | $73.2M | ||
| Q2 25 | $136.1M | $72.8M | ||
| Q1 25 | $123.6M | $74.5M | ||
| Q4 24 | $124.3M | $72.5M | ||
| Q3 24 | $115.9M | $78.5M | ||
| Q2 24 | $116.3M | $78.5M | ||
| Q1 24 | $108.9M | $78.3M |
净利润ATRCRMAX
| Q4 25 | — | $1.4M | ||
| Q3 25 | $-267.0K | $4.0M | ||
| Q2 25 | $-6.2M | $4.7M | ||
| Q1 25 | $-6.7M | $-2.0M | ||
| Q4 24 | — | $5.8M | ||
| Q3 24 | $-7.9M | $966.0K | ||
| Q2 24 | $-8.0M | $3.7M | ||
| Q1 24 | $-13.3M | $-3.4M |
毛利率ATRCRMAX
| Q4 25 | 75.0% | — | ||
| Q3 25 | 75.5% | — | ||
| Q2 25 | 74.5% | — | ||
| Q1 25 | 74.9% | — | ||
| Q4 24 | 74.5% | — | ||
| Q3 24 | 74.9% | — | ||
| Q2 24 | 74.7% | — | ||
| Q1 24 | 74.7% | — |
营业利润率ATRCRMAX
| Q4 25 | 1.8% | 13.1% | ||
| Q3 25 | 0.2% | 25.0% | ||
| Q2 25 | -4.5% | 19.3% | ||
| Q1 25 | -4.8% | 7.2% | ||
| Q4 24 | -11.7% | 5.9% | ||
| Q3 24 | -6.4% | 19.4% | ||
| Q2 24 | -6.2% | 20.6% | ||
| Q1 24 | -10.0% | 5.8% |
净利率ATRCRMAX
| Q4 25 | — | 2.0% | ||
| Q3 25 | -0.2% | 5.4% | ||
| Q2 25 | -4.5% | 6.4% | ||
| Q1 25 | -5.5% | -2.6% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | -6.8% | 1.2% | ||
| Q2 24 | -6.9% | 4.7% | ||
| Q1 24 | -12.2% | -4.3% |
每股收益（稀释后）ATRCRMAX
| Q4 25 | $0.04 | — | ||
| Q3 25 | $-0.01 | — | ||
| Q2 25 | $-0.13 | — | ||
| Q1 25 | $-0.14 | — | ||
| Q4 24 | $-0.33 | — | ||
| Q3 24 | $-0.17 | — | ||
| Q2 24 | $-0.17 | — | ||
| Q1 24 | $-0.28 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.4M | $118.7M |
| 总债务越低越好 | — | $432.2M |
| 股东权益账面价值 | $491.9M | $452.4M |
| 总资产 | $654.2M | $582.5M |
| 负债/权益比越低杠杆越低 | — | 0.96× |
8季度趋势，按日历期对齐
现金及短期投资ATRCRMAX
| Q4 25 | $167.4M | $118.7M | ||
| Q3 25 | $147.9M | $107.5M | ||
| Q2 25 | $117.8M | $94.3M | ||
| Q1 25 | $99.9M | $89.1M | ||
| Q4 24 | $122.7M | $96.6M | ||
| Q3 24 | $130.3M | $83.8M | ||
| Q2 24 | $114.0M | $66.1M | ||
| Q1 24 | $106.0M | $82.1M |
总债务ATRCRMAX
| Q4 25 | — | $432.2M | ||
| Q3 25 | $61.9M | $433.3M | ||
| Q2 25 | $61.9M | $434.4M | ||
| Q1 25 | $61.9M | $435.3M | ||
| Q4 24 | — | $436.2M | ||
| Q3 24 | $61.9M | $437.2M | ||
| Q2 24 | $61.9M | $438.1M | ||
| Q1 24 | $61.9M | $439.0M |
股东权益ATRCRMAX
| Q4 25 | $491.9M | $452.4M | ||
| Q3 25 | $476.5M | $448.1M | ||
| Q2 25 | $464.5M | $442.4M | ||
| Q1 25 | $454.6M | $433.5M | ||
| Q4 24 | $461.0M | $429.5M | ||
| Q3 24 | $465.0M | $423.1M | ||
| Q2 24 | $462.1M | $418.4M | ||
| Q1 24 | $456.3M | $412.0M |
总资产ATRCRMAX
| Q4 25 | $654.2M | $582.5M | ||
| Q3 25 | $635.4M | $582.2M | ||
| Q2 25 | $608.8M | $574.8M | ||
| Q1 25 | $591.6M | $571.4M | ||
| Q4 24 | $609.3M | $581.6M | ||
| Q3 24 | $615.1M | $578.6M | ||
| Q2 24 | $597.3M | $571.4M | ||
| Q1 24 | $591.6M | $566.7M |
负债/权益比ATRCRMAX
| Q4 25 | — | 0.96× | ||
| Q3 25 | 0.13× | 0.97× | ||
| Q2 25 | 0.13× | 0.98× | ||
| Q1 25 | 0.14× | 1.00× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | 0.13× | 1.03× | ||
| Q2 24 | 0.13× | 1.05× | ||
| Q1 24 | 0.14× | 1.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $20.0M | $40.9M |
| 自由现金流经营现金流 - 资本支出 | $18.4M | $33.5M |
| 自由现金流率自由现金流/营收 | 13.1% | 47.1% |
| 资本支出强度资本支出/营收 | 1.1% | 10.4% |
| 现金转化率经营现金流/净利润 | — | 28.39× |
| 过去12个月自由现金流最近4个季度 | $48.3M | $56.8M |
8季度趋势，按日历期对齐
经营现金流ATRCRMAX
| Q4 25 | $20.0M | $40.9M | ||
| Q3 25 | $26.7M | $17.7M | ||
| Q2 25 | $21.6M | $4.6M | ||
| Q1 25 | $-11.0M | $5.7M | ||
| Q4 24 | $5.8M | $59.7M | ||
| Q3 24 | $20.0M | $17.6M | ||
| Q2 24 | $7.4M | $15.9M | ||
| Q1 24 | $-21.0M | $9.4M |
自由现金流ATRCRMAX
| Q4 25 | $18.4M | $33.5M | ||
| Q3 25 | $24.1M | $16.4M | ||
| Q2 25 | $19.0M | $2.9M | ||
| Q1 25 | $-13.2M | $4.0M | ||
| Q4 24 | $3.1M | $53.0M | ||
| Q3 24 | $16.4M | $16.3M | ||
| Q2 24 | $5.0M | $14.0M | ||
| Q1 24 | $-23.8M | $6.8M |
自由现金流率ATRCRMAX
| Q4 25 | 13.1% | 47.1% | ||
| Q3 25 | 18.0% | 22.4% | ||
| Q2 25 | 13.9% | 4.0% | ||
| Q1 25 | -10.7% | 5.3% | ||
| Q4 24 | 2.5% | 73.2% | ||
| Q3 24 | 14.1% | 20.8% | ||
| Q2 24 | 4.3% | 17.8% | ||
| Q1 24 | -21.9% | 8.6% |
资本支出强度ATRCRMAX
| Q4 25 | 1.1% | 10.4% | ||
| Q3 25 | 1.9% | 1.8% | ||
| Q2 25 | 2.0% | 2.2% | ||
| Q1 25 | 1.8% | 2.3% | ||
| Q4 24 | 2.2% | 9.1% | ||
| Q3 24 | 3.1% | 1.7% | ||
| Q2 24 | 2.1% | 2.4% | ||
| Q1 24 | 2.5% | 3.3% |
现金转化率ATRCRMAX
| Q4 25 | — | 28.39× | ||
| Q3 25 | — | 4.45× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 10.28× | ||
| Q3 24 | — | 18.22× | ||
| Q2 24 | — | 4.29× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATRC
| Appendage Management | $45.5M | 32% |
| Openheart | $38.5M | 27% |
| Other | $26.2M | 19% |
| Pain Management | $22.6M | 16% |
| Minimally Invasive | $7.7M | 6% |
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
